布基纳法索婴儿单剂阿奇霉素促进生长:随机对照试验的预设次要人体测量结局
在布基纳法索农村开展随机对照试验,婴儿在5至12周龄健康访视时单次口服阿奇霉素20 mg/kg或安慰剂,6月龄时随访27,298名(83%)婴儿有有效人体测量数据,未发现体重增长、身长变化及各Z评分和上臂围的差异。
要点
- 单次口服阿奇霉素20 mg/kg与安慰剂相比,6月龄时体重增长平均差0.03 g/天(95%CI -0.12至0.18)。
- 身长变化平均差0.004 mm/天(95%CI -0.05至0.06),上臂围平均差0.01 cm(95%CI -0.01至0.04)。
- WAZ、WLZ、LAZ平均差分别为-0.004 SD、0.001 SD、-0.005 SD,均无统计学显著差异。
核心结论
- 单剂阿奇霉素在早期婴儿期给药似乎不影响体重和身长结局。
研究设计与样本
- 随机对照试验,2019年9月25日至2022年10月22日入组5至12周龄婴儿,单次口服阿奇霉素20 mg/kg或安慰剂。
- 共入组32,877名婴儿,27,298名(83%)在6月龄时随访并有有效人体测量数据。
主要发现
- 体重增长平均差0.03 g/天(95%CI -0.12至0.18)。
- 身长变化平均差0.004 mm/天(95%CI -0.05至0.06)。
- WAZ平均差-0.004 SD(95%CI -0.03至0.02)。
- WLZ平均差0.001 SD(95%CI -0.03至0.03)。
- LAZ平均差-0.005 SD(95%CI -0.03至0.02);上臂围平均差0.01 cm(95%CI -0.01至0.04)。
局限性
- 主要局限性是仅在入组时和6月龄时收集测量数据,无法评估短期或长期生长变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibiotic use during early infancy has been linked to childhood obesity in high-income countries. We evaluated whether a single oral dose of azithromycin administered during infant-well visits led to changes in infant growth outcomes at 6 months of age in a setting with a high prevalence of undernutrition in rural Burkina Faso. METHODS AND FINDINGS: Infants were enrolled from September 25, 2019, until October 22, 2022, in a randomized controlled trial designed to evaluate the efficacy of a single oral dose of azithromycin (20 mg/kg) compared to placebo when administered during well-child visits for prevention of infant mortality. The trial found no evidence of a difference in the primary endpoint. This paper presents prespecified secondary anthropometric endpoints including weight gain (g/day), height change (mm/day), weight-for-age Z-score (WAZ), weight-for-length Z-score (WLZ), length-for-age Z-score (LAZ), and mid-upper arm circumference (MUAC). Infants were eligible for the trial if they were between 5 and 12 weeks of age, able to orally feed, and their families were planning to remain in the study area for the duration of the study. Anthropometric measurements were collected at enrollment (5 to 12 weeks of age) and 6 months of age. Among 32,877 infants enrolled in the trial, 27,298 (83%) were followed and had valid anthropometric measurements at 6 months of age. We found no evidence of a difference in weight gain (mean difference 0.03 g/day, 95% confidence interval (CI) -0.12 to 0.18), height change (mean difference 0.004 mm/day, 95% CI -0.05 to 0.06), WAZ (mean difference -0.004 SD, 95% CI -0.03 to 0.02), WLZ (mean difference 0.001 SD, 95% CI -0.03 to 0.03), LAZ (mean difference -0.005 SD, 95% CI -0.03 to 0.02), or MUAC (mean difference 0.01 cm, 95% CI -0.01 to 0.04). The primary limitation of the trial was that measurements were only collected at enrollment and 6 months of age, precluding assessment of shorter-term or long-term changes in growth. CONCLUSIONS: Single-dose azithromycin does not appear to affect weight and height outcomes when administered during early infancy. TRIAL REGISTRATION: ClinicalTrials.gov NCT03676764.
引用
- Sié A, Ouattara M, Bountogo M, et al. Single-dose azithromycin for infant growth in Burkina Faso: Prespecified secondary anthropometric outcomes from a randomized controlled trial. PLoS Med. 2024. PMID: 38261579. doi:10.1371/journal.pmed.1004345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。